Scinai Immunotherapeutics (NASDAQ:SCNI) reported its financial and operational results for the fiscal year ended December 31, 2025, on Wednesday, April 1, 2026.
The results underscore a period of rapid evolution for the company’s Contract Development and Manufacturing Organization (CDMO) business unit, which has become a primary engine for top-line growth.
For the full year, Scinai’s CDMO revenues doubled to $1.3 million, up from $0.7 million in 2024.
This growth was driven by a successful expansion of the company’s client base and the execution of multiple development programs for third-party biotech firms.
Despite the revenue gains, Scinai reported a net loss of $8.3 million, compared to a net income of $4.8 million in the prior year.
Management noted that the 2024 results were heavily influenced by one-time financial income from a loan conversion that did not recur in 2025.
The company ended the fiscal year with a cash position of $1.8 million, supported by a disciplined reduction in R&D spending as the company shifts toward a more capital-efficient, partner-aligned development model.